CIBIS

AcronymDefinition
CIBISCorporate Internet Business Information Systems (Newcastle, New South Wales, Australia)
References in periodicals archive ?
The CIBIS III trial compared bisoprolol first and enalapril first regimens.
CIBIS Investigators and Committees, A randomized trial of beta-blockade in heart failure.
Congestive heart failure in Indians: how do we improve diagnosis & management?
In CIBIS II, 15% of the patients randomized to bisoprolol stopped taking it; (1) in COPERNICUS, the withdrawal rate from carvedilol was also 15%; (2) and in MERIT-HE 10% of patients taking metoprolol experienced an adverse event that led to drug withdrawal.
TABLE 1 Beta-blockers for heart failure patients: What the studies show Mean Agent Trial Study group (N) follow-up tested BESTS Class III-IV HF EF 2 y Bucindolol [less than or equal to] 535% (2708) CIBIS II (1) Class III-IV HF EF 1.
Beta-blockers for heart failure: why you should use them more: many physicians are afraid to prescribe beta-blockers for patients with heart failure. Yet in most cases, not prescribing them is a mistake
This is precisely the purpose of the CIBIS III trial, which aims to answer the question of whether initiation of CHF therapy with a beta-blocker is comparable (non-inferior) to the initiation of therapy with an ACE inhibitor.
Guidant and Merck KGaA Continue Collaboration on Heart Failure Education
However, the results are not inconsistent with those of other studies, specifically MERIT-HF and CIBIS II.
BEXTRA Trial Terminated With No Statistically Significant Survival Advantage
TABLE Selected trials of beta-blockers for systolic dysfunction Mortality reduction 95% Study Drug N (%) CI (%) US Carvedilol (1) Carvedilol 1094 (65) 39-80 COPERNICUS (2) Carvedilol 2289 (35) 19-48 MERIT-HF (3) Metoprolol 3991 (34) 19-46 CIBIS II (4) Bisoprolol 2647 (34) 19-47 BEST (5) Bucindolol 2708 (9) -0.
What is the most effective beta-blocker for heart failure? (Clinical inquiries: from the Family Practice Inquiries Network)
FIGURE EFFECT OF B-BLOCKER THERAPY ON TOTAL MORTALITY [ILLUSTRATION OMITTED] Clinical Trial [Beta]-Blocker Placebo (Number of deaths/ number at risk) CIBIS[11] 53/320 67/321 CIBIS-II[12] 156/1327 228/1320 ANZ[9] 20/208 26/207 US Carvedilol[13] 22/696 31/398 MDC[14] 23/194 19/189 MERIT-HF[3] 145/1990 217/2001 Overall -- -- CIBIS denotes Cardiac Insufficiency Bisoprolol Study; CIBIS-II, Cardiac Insufficiency Bisoprolol Study II; ANZ, Australia/New Zealand Heart Failure Research Collaborative Trial; US Carvedilol, US Carvedilol Heart Failure Program; MDC, Metoprolol in Dilated Cardiomyopathy trial; MERIT-HF, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart
Beta-Blockers to Reduce Mortality in Patients with Systolic Dysfunction
Acronyms browser ?
Full browser ?